Floatz logo

cd123-cd33 ccar t cells

Hematologic Malignancy

iCell Gene TherapeuticsCell therapyEarly Phase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Hematologic Malignancy cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

cd123-cd33 ccar t cells is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →
myeloproliferative neoplasmDormant
C
Indicative ·
38 / 100
View asset →
chronic myeloid leukemiaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →